Suboxone is not approved to treat depression, but its active ingredient, buprenorphine, does appear to have real antidepressant effects. A systematic review covering 13 studies found that buprenorphine, whether used alone or combined with an opioid-blocking agent, significantly reduced depressive symptoms across every study examined. Some patients with treatment-resistant depression experienced complete remission. Still, using Suboxone specifically for depression is off-label, and the doses studied for mood disorders are far lower than those typically prescribed for opioid addiction.
Why Buprenorphine Affects Mood
Buprenorphine, the primary ingredient in Suboxone, interacts with your brain’s opioid system in a way that standard antidepressants do not. It partially activates mu-opioid receptors, the same receptors involved in pain relief and feelings of well-being. But what makes it particularly interesting for depression is its second role: it blocks kappa-opioid receptors. Kappa receptors are closely linked to feelings of dysphoria, stress, and low mood. When those receptors are overactive, people tend to feel worse. By blocking them, buprenorphine may directly counteract one of the biological drivers of depression.
This dual action sets buprenorphine apart from conventional antidepressants like SSRIs, which work on serotonin pathways. It targets a completely different system in the brain, which helps explain why it has shown promise in people whose depression didn’t respond to standard medications.
What the Clinical Evidence Shows
Most of the research on buprenorphine for depression has focused on treatment-resistant depression, meaning patients who tried standard antidepressants without adequate relief. The results, while from relatively small studies, have been consistently positive.
In one trial, 10 patients with treatment-resistant depression were given low-dose buprenorphine for four to six weeks. Seven of them showed “clinically striking improvements” in both how they felt and how clinicians rated their symptoms. Another study of 15 patients found the sharpest drop in depression scores during the first three weeks of treatment. A smaller trial of six patients reported improvement after just seven days. Across multiple studies, some patients achieved full remission.
The speed of response is notable. Several trials observed meaningful improvement within the first week of treatment. That’s considerably faster than SSRIs, which typically take four to six weeks to reach full effect. For people in acute distress, that rapid onset could matter a great deal.
Larger trials have also tested buprenorphine paired with samidorphan (an opioid blocker similar to the naloxone in Suboxone) as an add-on treatment for people already taking antidepressants. One major trial called FORWARD-5 met its primary goal, showing the combination was significantly better than placebo at reducing depression scores. A second trial, FORWARD-4, narrowly missed its primary endpoint but showed significant improvement at several time points. When both trials were pooled together, the antidepressant effect was statistically significant.
Depression Improvement During Addiction Treatment
If you’re taking Suboxone for opioid use disorder and noticing your mood improve, you’re not imagining it. In a large 10-site trial of 360 people receiving buprenorphine-naloxone (Suboxone) for prescription opioid addiction, depressive symptoms decreased significantly throughout treatment. This likely reflects a combination of factors: the direct pharmacological effect of buprenorphine on mood-related brain circuits, the psychological relief of getting addiction under control, and the stabilization that comes with consistent treatment.
That said, the study also found that improvement in depression didn’t predict better opioid-related outcomes. Depression relief and addiction recovery appear to follow somewhat independent tracks, meaning you can feel better emotionally while still needing to stay engaged with your addiction treatment plan.
Doses for Depression vs. Addiction
One of the most important distinctions in this research is dosage. Suboxone for opioid use disorder is typically prescribed at 8 to 24 mg per day. The doses studied for depression are dramatically lower, often between 0.2 and 2 mg per day. In one trial of older adults with treatment-resistant depression, the average maximum dose was just 0.7 mg daily.
Interestingly, higher doses don’t seem to work better for mood. In the FORWARD trials, the lower-dose group (2 mg buprenorphine/2 mg samidorphan) showed greater depression reduction than the higher-dose group (8 mg/8 mg), where improvements didn’t reach statistical significance. The antidepressant sweet spot appears to be at doses low enough to modulate the opioid system without producing the sedation or euphoria associated with higher amounts.
This means that the standard Suboxone dose prescribed for opioid addiction is much higher than what researchers have tested for depression. If you’re on Suboxone for addiction and noticing mood benefits, the effect may be real, but it’s arriving through a different dose range than what’s been optimized for mood.
It’s Not FDA-Approved for Depression
Despite promising trial results, no buprenorphine-based medication has received FDA approval for depression as of mid-2025. Buprenorphine is currently in Phase 3 clinical trials as an add-on treatment for major depression, specifically targeting severe suicidal ideation. The path to approval has been slowed by mixed results in the larger trials: one succeeded, one fell just short, and regulators have held off.
Any use of Suboxone or buprenorphine for depression right now is off-label. Some psychiatrists do prescribe low-dose buprenorphine for treatment-resistant cases, but it’s far from standard practice. The systematic review of existing evidence concluded that low-dose buprenorphine is “efficacious, well-tolerated, and safe” for reducing depressive symptoms, but the total number of patients studied remains small, around 216 across all treatment-resistant depression trials combined.
Risks and Side Effects
Buprenorphine carries side effects regardless of why you’re taking it. The most common include constipation, headache, nausea, dizziness, drowsiness, sweating, and dry mouth. Tooth decay is a recognized concern with longer-term use. More serious risks include respiratory problems (especially when combined with sedatives or alcohol), physical dependence, and withdrawal symptoms if stopped abruptly.
The dependence risk is particularly relevant for people considering buprenorphine purely for depression. Because it activates opioid receptors, your body can become physically dependent on it over time, and stopping requires a gradual taper. For someone already taking Suboxone for opioid addiction, this is an expected part of treatment. For someone without an opioid history, introducing any opioid-acting medication carries a different risk calculation. Misuse potential exists, particularly in people without opioid tolerance.
The low doses used in depression studies do appear to carry fewer of these risks than the higher doses used for addiction treatment. Across the clinical trials, researchers consistently described the low-dose regimens as well-tolerated. But even at low doses, buprenorphine is not a casual addition to a medication regimen.